This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Study Type
OBSERVATIONAL
Enrollment
20
Reduced-intensity fludarabine with intermediate-dose TBI
Caitlin Guzowski
Atlanta, Georgia, United States
RECRUITINGCompare the time to recovery of circulating neutrophils and platelets of all patients to determine incidence of graft rejection
Time frame: 30 days after transplant
Number of patients who are still alive as assessed by survival status at certain timepoints after transplant
Time frame: 36 months after transplant
Number of patients with relapsed disease as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant
Time frame: 36 months after transplant
Number of patients with evidence of graft versus host disease as assessed by weekly progress notes after transplant
Time frame: 36 months after transplant
Number of participants who died in the absence of relapse or progression as assessed by survival status at certain timepoints after transplant
Time frame: 1 year after transplant
Number of participants with responses to treatment as assessed by labs, bone marrow biopsies and radiological scans at certain timepoints after transplant
Time frame: 36 months after transplant
Number of participants with treatment-related adverse events as assessed by CTCAE v.5.0
Time frame: 90 days after transplant
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.